Evidence map›Paper›PMID 36778475›Full record

ArticleResearch square2023

Regulation of Ferroptosis by Transcription Factor E2F1 and RB.

Nishanth Kuganesan, Samkeliso Dlamini, Viranga Lm Tillekeratne, William R Taylor

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nishanth KuganesanUniversity of Toledo.
Samkeliso DlaminiUniversity of Toledo.
Viranga Lm TillekeratneUniversity of Toledo.
William R TaylorUniversity of Toledo.
University of Toledo · US

Funding

Regulation of Ferroptosis by the p53/CDK/Rb Axis.R15GM141712 · NIGMS · UNIVERSITY OF TOLEDO · PI TAYLOR, WILLIAM R. · 2021 to 2022
$464k
Novel Small Molecule Ferroptotic Compounds to Target Mesenchymal Breast Cancer and Breast Cancer Stem CellsR15CA213185 · NCI · UNIVERSITY OF TOLEDO · PI TILLEKERATNE, VIRANGA · 2018 to 2018
$449k
NCI NIH HHS R15 CA213185NIGMS NIH HHS R15 GM141712
6 · The paper itself

Abstract

Tumor suppressor RB binds to E2F family proteins and modulates cell cycle progression. Cyclin dependent kinases (CDK) regulate the interaction of RB/E2F by phosphorylating RB. Previously, we have revealed that CDK2, RB and E2F inhibit ferroptosis. Ferroptosis is a non-apoptotic, iron-dependent form of cell death characterized by toxic lipid peroxidation. Here we provide evidence that CDK2 suppresses ferroptosis through phosphorylation of RB. We approach this question by overexpressing WT-RB or a mutant RB that cannot be phosphorylated by CDKs (RBΔCDK) along with CDK2/cyclinE followed by analysis of ferroptosis. We also observed that E2F1 regulates of both pro and anti-ferroptotic proteins including ALOX5, MYC SLC7A11, ATF4, and GPX4 and finally renders a net inhibitory role in ferroptosis. Interestingly, we also found a cell type dependent compensatory effect of E2F3 upon E2F1 depletion. This compensatory effect resulted in no change of ferroptotic target genes after E2F1 knock down in an osteosarcoma cell line. Taken together, our study reveals that cancer cells protect themselves from ferroptosis through cell cycle regulatory proteins.

Indexed as

cyclin dependent kinase (CDK)cyclin EE2Fferroptosisretinoblastoma protein (RB)SLC7A11

Identifiers

PMID36778475
PMCPMC9915776
OpenAlexW4318574652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.